Aberrant CDX2 expression in hepatocellular carcinomas: An important diagnostic pitfall

Sejal M Shah, Tsung-Teh Wu, Michael Torbenson, Vishal S. Chandan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

CDX2 is a sensitive and specific marker of intestinal differentiation. It is routinely used in surgical pathology, as its expression within a tumor favors an origin within the gastrointestinal tract. We had anecdotally encountered occasional hepatocellular carcinomas (HCCs) that were CDX2 positive. CDX2 expression in HCC has not yet been reported, but it has also not been examined in detail. Therefore, we evaluated CDX2 expression in a large number of resected HCCs. Full tumor sections from 172 resected HCCs and 6 resected fibrolamellar carcinomas (FLCs) were stained for CDX2. Nine (5.2%) of 172 HCCs were positive for CDX2, whereas all 6 FLCs were negative. CDX2 expression in HCCs was more commonly seen in poorly differentiated tumors (5 of 16 cases, 31%) than well and moderately differentiated tumors (4 of 156 cases, 2.5%), P =.0004. No other statistically significant correlations were observed (P > .05). Results of our study show that a small subset (5%) of HCCs can be CDX2 positive. Awareness of this phenomenon is important because CDX2 expression in a liver tumor does not completely exclude a diagnosis of HCC.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalHuman Pathology
Volume64
DOIs
StatePublished - Jun 1 2017

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Carcinoma
Surgical Pathology
Differentiation Antigens
Gastrointestinal Tract
Liver

Keywords

  • CDX2
  • Fibrolamellar carcinoma
  • Hepatocellular carcinoma
  • Liver
  • Metastasis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Aberrant CDX2 expression in hepatocellular carcinomas : An important diagnostic pitfall. / Shah, Sejal M; Wu, Tsung-Teh; Torbenson, Michael; Chandan, Vishal S.

In: Human Pathology, Vol. 64, 01.06.2017, p. 13-18.

Research output: Contribution to journalArticle

Shah, Sejal M ; Wu, Tsung-Teh ; Torbenson, Michael ; Chandan, Vishal S. / Aberrant CDX2 expression in hepatocellular carcinomas : An important diagnostic pitfall. In: Human Pathology. 2017 ; Vol. 64. pp. 13-18.
@article{bc9e7225d0504234a5cc59eedf2d4b3f,
title = "Aberrant CDX2 expression in hepatocellular carcinomas: An important diagnostic pitfall",
abstract = "CDX2 is a sensitive and specific marker of intestinal differentiation. It is routinely used in surgical pathology, as its expression within a tumor favors an origin within the gastrointestinal tract. We had anecdotally encountered occasional hepatocellular carcinomas (HCCs) that were CDX2 positive. CDX2 expression in HCC has not yet been reported, but it has also not been examined in detail. Therefore, we evaluated CDX2 expression in a large number of resected HCCs. Full tumor sections from 172 resected HCCs and 6 resected fibrolamellar carcinomas (FLCs) were stained for CDX2. Nine (5.2{\%}) of 172 HCCs were positive for CDX2, whereas all 6 FLCs were negative. CDX2 expression in HCCs was more commonly seen in poorly differentiated tumors (5 of 16 cases, 31{\%}) than well and moderately differentiated tumors (4 of 156 cases, 2.5{\%}), P =.0004. No other statistically significant correlations were observed (P > .05). Results of our study show that a small subset (5{\%}) of HCCs can be CDX2 positive. Awareness of this phenomenon is important because CDX2 expression in a liver tumor does not completely exclude a diagnosis of HCC.",
keywords = "CDX2, Fibrolamellar carcinoma, Hepatocellular carcinoma, Liver, Metastasis",
author = "Shah, {Sejal M} and Tsung-Teh Wu and Michael Torbenson and Chandan, {Vishal S.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.humpath.2016.12.029",
language = "English (US)",
volume = "64",
pages = "13--18",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Aberrant CDX2 expression in hepatocellular carcinomas

T2 - An important diagnostic pitfall

AU - Shah, Sejal M

AU - Wu, Tsung-Teh

AU - Torbenson, Michael

AU - Chandan, Vishal S.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - CDX2 is a sensitive and specific marker of intestinal differentiation. It is routinely used in surgical pathology, as its expression within a tumor favors an origin within the gastrointestinal tract. We had anecdotally encountered occasional hepatocellular carcinomas (HCCs) that were CDX2 positive. CDX2 expression in HCC has not yet been reported, but it has also not been examined in detail. Therefore, we evaluated CDX2 expression in a large number of resected HCCs. Full tumor sections from 172 resected HCCs and 6 resected fibrolamellar carcinomas (FLCs) were stained for CDX2. Nine (5.2%) of 172 HCCs were positive for CDX2, whereas all 6 FLCs were negative. CDX2 expression in HCCs was more commonly seen in poorly differentiated tumors (5 of 16 cases, 31%) than well and moderately differentiated tumors (4 of 156 cases, 2.5%), P =.0004. No other statistically significant correlations were observed (P > .05). Results of our study show that a small subset (5%) of HCCs can be CDX2 positive. Awareness of this phenomenon is important because CDX2 expression in a liver tumor does not completely exclude a diagnosis of HCC.

AB - CDX2 is a sensitive and specific marker of intestinal differentiation. It is routinely used in surgical pathology, as its expression within a tumor favors an origin within the gastrointestinal tract. We had anecdotally encountered occasional hepatocellular carcinomas (HCCs) that were CDX2 positive. CDX2 expression in HCC has not yet been reported, but it has also not been examined in detail. Therefore, we evaluated CDX2 expression in a large number of resected HCCs. Full tumor sections from 172 resected HCCs and 6 resected fibrolamellar carcinomas (FLCs) were stained for CDX2. Nine (5.2%) of 172 HCCs were positive for CDX2, whereas all 6 FLCs were negative. CDX2 expression in HCCs was more commonly seen in poorly differentiated tumors (5 of 16 cases, 31%) than well and moderately differentiated tumors (4 of 156 cases, 2.5%), P =.0004. No other statistically significant correlations were observed (P > .05). Results of our study show that a small subset (5%) of HCCs can be CDX2 positive. Awareness of this phenomenon is important because CDX2 expression in a liver tumor does not completely exclude a diagnosis of HCC.

KW - CDX2

KW - Fibrolamellar carcinoma

KW - Hepatocellular carcinoma

KW - Liver

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=85019231042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019231042&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.12.029

DO - 10.1016/j.humpath.2016.12.029

M3 - Article

C2 - 28089540

AN - SCOPUS:85019231042

VL - 64

SP - 13

EP - 18

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -